NCT06336330

Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany

Early Treatment of Heart Failure: a Non-interventional Study Program of Patients With Heart Failure and Initiated on Dapagliflozin (EVOLUTION-HF DEallEF)

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 765 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 130 Years
• Healthy volunteers: Not accepted

Summary

Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide; this burden is expected to increase substantially as the population ages. Despite advancements in treatment, a HF diagnosis still leads to significant morbidity and mortality; there is also an immense impact on patients' health-related quality of life (HRQoL). Dapagliflozin was recently granted approval for heart failure by the European Commission, regardless of ejection fraction and whether the patient has diabetes. Real-world observational data are necessary to describe dapagliflozin use in real-world settings in order to assess treatment patterns, HF symptoms and their impact on physical limitation, HRQoL and work productivity, as well as health care utilization of patients treated with dapagliflozin in this setting under local treatment standard conditions in Germany.

Conditions

• Heart Diseases
• Cardiovascular Diseases
• Heart Failure

Timeline

• Start date: 2024-04-25
• Primary completion: 2026-12-31
• Completion: 2026-12-31
• First posted: 2024-03-28
• Last updated: 2026-01-16

Locations

47 sites across 1 country: Germany